Table 2. The pooled results for glycated hemoglobin level and weight reduction on comparison of glucagon-like peptide-1 receptor agonist and placebo by using the structural equation modeling multivariate meta-analysis according to participant characteristics.
| All participants | Patients with diabetes | Patients without diabetes | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Setting r = 0.2 | Estimates (95% CI) | p | I 2 | Estimates (95% CI) | p | I 2 | Estimates (95% CI) | p | I 2 |
| Glycated hemoglobin (%) | -0.85 (-1.03, -0.66) | <0.001 | 99% | -0.96 (-1.14, -0.79) | <0.001 | 96% | -0.27 (-0.31, -0.23) | <0.001 | 13% |
| Body weight (kg) | -4.03 (-5.11, -2.95) | <0.001 | 99% | -3.23 (-3.86, -2.59) | <0.001 | 95% | -6.76 (-10.81, -2.72) | 0.001 | 99% |
| tao of glycated hemoglobin | 0.18 (0.07, 0.30) | <0.001 | 0.13 (0.03, 0.23) | 0.008 | 0 | 0.909 | |||
| tao of body weight | 7.36 (3.10, 11.63) | <0.001 | 1.77 (0.56, 2.99) | 0.004 | 20.84 (-5.32, 47.00) | 0.118 | |||
| Covariance | -0.48 (-1.02, 0.05) | <0.001 | 0.15 (-0.12, 0.43) | 0.281 | 0.04 (-0.14, 0.21) | 0.682 | |||
| Standardized correlation coefficient | -0.42 | 0.32 | 0.81 | ||||||
CI, confidence interval; r, correlation coefficient between glycated hemoglobin and body weight changes within the study level; tao, the variance of effect measure